PL2605794T3 - Chelatowe kompleksy oligonukleotydów - Google Patents

Chelatowe kompleksy oligonukleotydów

Info

Publication number
PL2605794T3
PL2605794T3 PL11817618T PL11817618T PL2605794T3 PL 2605794 T3 PL2605794 T3 PL 2605794T3 PL 11817618 T PL11817618 T PL 11817618T PL 11817618 T PL11817618 T PL 11817618T PL 2605794 T3 PL2605794 T3 PL 2605794T3
Authority
PL
Poland
Prior art keywords
chelate complexes
oligonucleotide chelate
oligonucleotide
complexes
chelate
Prior art date
Application number
PL11817618T
Other languages
English (en)
Polish (pl)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2605794(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of PL2605794T3 publication Critical patent/PL2605794T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
PL11817618T 2010-08-20 2011-08-18 Chelatowe kompleksy oligonukleotydów PL2605794T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
PL2605794T3 true PL2605794T3 (pl) 2017-01-31

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11817618T PL2605794T3 (pl) 2010-08-20 2011-08-18 Chelatowe kompleksy oligonukleotydów

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC7.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC7.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC7.html)
KR (3) KR101606495B1 (cg-RX-API-DMAC7.html)
CN (2) CN103052405B (cg-RX-API-DMAC7.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC7.html)
CA (2) CA2806616C (cg-RX-API-DMAC7.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC7.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130069A (cg-RX-API-DMAC7.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC7.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC7.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC7.html)
EA (1) EA026660B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC7.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300040A (cg-RX-API-DMAC7.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC7.html)
IL (1) IL224237A (cg-RX-API-DMAC7.html)
LT (1) LT2605794T (cg-RX-API-DMAC7.html)
MX (1) MX340294B (cg-RX-API-DMAC7.html)
MY (1) MY160961A (cg-RX-API-DMAC7.html)
NZ (1) NZ606364A (cg-RX-API-DMAC7.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC7.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC7.html)
PT (1) PT2605794T (cg-RX-API-DMAC7.html)
RS (1) RS55245B1 (cg-RX-API-DMAC7.html)
SG (1) SG187165A1 (cg-RX-API-DMAC7.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600370B (cg-RX-API-DMAC7.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
ES2564563T3 (es) 2007-10-26 2016-03-23 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar trastornos del músculo
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP4400169A3 (en) 2012-04-23 2024-12-25 Vico Therapeutics B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
TWI635864B (zh) * 2012-05-18 2018-09-21 雷普利可公司 寡核苷酸螯合複合物-多肽組合物及方法
CN110257379B (zh) 2012-07-03 2023-08-11 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) * 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
SMT202000389T1 (it) * 2015-04-23 2020-09-10 Geron Corp Metodi di preparazione di polinucleotidi usando composizioni di sali cationici multivalenti
CN113286803A (zh) * 2018-11-08 2021-08-20 阿里戈斯治疗公司 S-抗原转运抑制寡核苷酸聚合物和方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021198958A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Nucleic acid polymers
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US20240336921A1 (en) 2021-07-09 2024-10-10 Glaxo Smith Kline Intellectual Property (No. 3) Limited Use of oligonucleotides for individuals with renal impairment
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019429A4 (en) * 1997-08-20 2001-08-08 Somagenics Inc ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および/また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
EP2605794A4 (en) 2014-07-02
HK1184058A1 (zh) 2014-01-17
HUE029521T2 (en) 2017-03-28
CN103052405B (zh) 2015-11-25
PH12013500192A1 (cg-RX-API-DMAC7.html) 2013-03-11
HK1198123A1 (en) 2015-03-13
BR112013003875B1 (pt) 2021-10-05
AU2011291401B2 (en) 2014-11-27
PT2605794T (pt) 2016-10-25
AU2011291401A1 (en) 2013-01-10
CR20130069A (es) 2013-09-20
SMT201600370B (it) 2016-11-10
NZ606364A (en) 2014-12-24
JP2013536195A (ja) 2013-09-19
KR20150039873A (ko) 2015-04-13
SI2605794T1 (sl) 2017-01-31
ECSP13012449A (es) 2013-04-30
CA2855690A1 (en) 2012-02-23
KR20130099067A (ko) 2013-09-05
MX340294B (es) 2016-07-04
CA2806616A1 (en) 2012-02-23
IL224237A (en) 2015-09-24
MX2013001668A (es) 2013-07-22
MY160961A (en) 2017-03-31
EP2605794B1 (en) 2016-07-20
US8716259B2 (en) 2014-05-06
SG187165A1 (en) 2013-02-28
CL2013000445A1 (es) 2013-11-22
ZA201300497B (en) 2013-09-25
KR20150082685A (ko) 2015-07-15
CA2806616C (en) 2015-08-11
LT2605794T (lt) 2016-10-25
EA201300259A1 (ru) 2013-12-30
RS55245B1 (sr) 2017-02-28
JP5775581B2 (ja) 2015-09-09
US20120046348A1 (en) 2012-02-23
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
GT201300040A (es) 2014-09-02
US8513211B2 (en) 2013-08-20
DOP2013000041A (es) 2017-12-15
DK2605794T3 (en) 2016-10-24
CA2855690C (en) 2015-08-25
CN103052405A (zh) 2013-04-17
CO6670525A2 (es) 2013-05-15
HRP20161333T1 (hr) 2016-12-02
CU20130022A7 (es) 2013-04-19
CN103768086B (zh) 2015-10-14
EA026660B1 (ru) 2017-05-31
CN103768086A (zh) 2014-05-07
KR101606495B1 (ko) 2016-03-28
EP2605794A1 (en) 2013-06-26
US20130296410A1 (en) 2013-11-07
PH12013500192B1 (en) 2018-11-23
BR112013003875A2 (en) 2018-03-13
WO2012021985A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
ZA201300497B (en) Oligonucleotide chelate complexes
IL221416A0 (en) Alpha-emititng complexes
PT2585216T (pt) Complexos de п-alilpaládio e п-alilníquel para utilização como catalisadores em reações de acoplamento de carbono-carbono e carbono-azoto
IL212941A0 (en) Usirna complexes
IL226299A (en) Oligonucleotides that stimulate the immune system
GB201208309D0 (en) Complexes
EP2516407A4 (en) RADIOPHARMACEUTICAL COMPLEXES
ZA201408082B (en) Oligonucleotide chelate complex methods
ZA201206793B (en) Nucleic acid complexes
GB201014500D0 (en) Cytotoxic lumininescent metal complexes
GB201003483D0 (en) Gold complexes
PT2637704E (pt) Ligandos baseados em fenilimidazole radiomarcado
IL223111A0 (en) Ruthenium based complexes
GB201104522D0 (en) Complexes
PL393225A1 (pl) Automat załadowczo - wyładowczy
GB201010960D0 (en) Complex
GB0901231D0 (en) Ligands
LU91705B1 (en) Expresso-making machine
IL223703A (en) Ruthenium-based complexes
TWM386767U (en) Baking machine
GB201000782D0 (en) Jukeboxes
GB201005227D0 (en) 4-Pin pegbar
GB201014865D0 (en) Concept 36A
GB201210358D0 (en) Complexes
GB0917576D0 (en) Novel estrogenreceptor ligands